BCD-085 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	1
271	Ankylosing spondylitis	2

93. Primary biliary cholangitis

Clinical trials : 282 / Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03476993 (ClinicalTrials.gov)	April 27, 2018	20/3/2018	Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis	Open-label Non-comparative Study to Evaluate the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis	Liver Cirrhosis, Biliary	Biological: BCD-085	Biocad	NULL	Terminated	18 Years	60 Years	All	9	Phase 2	Russian Federation

Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03447704 (ClinicalTrials.gov)	February 9, 2018	21/2/2018	International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis	An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: BCD-085;Other: placebo	Biocad	NULL	Active, not recruiting	18 Years	65 Years	All	228	Phase 3	Russian Federation
2	NCT02763111 (ClinicalTrials.gov)	September 2016	3/4/2016	Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis	International Multi-center Comparative Randomized Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Active Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: BCD-085;Other: Placebo	Biocad	NULL	Completed	18 Years	65 Years	All	88	Phase 2	NULL